Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: J Pharm Sci. 2016 Nov 11;106(1):331–337. doi: 10.1016/j.xphs.2016.09.033

Figure 2.

Figure 2

AVERAGE plasma concentration versus time curves (log scale) for all treatments administered by various routes and with different doses. Treatments include: intravenous ethionamide USP (IV; 6 mg/kg), oral ethionamide USP (Oral; 6 mg/kg), ethionamide large porous particles (ETH-PPs; 6 mg/kg), and ethionamide large porous particles delivered by nose-only exposure (ETH-PPs; 5 mg/kg). * = IV different from oral (P<0.05); # = insufflation different from oral (P<0.05). (Average ± standard deviation, n = 4–8).